EUVIMEDEUVIMED entdecken
Crossref

Experience with SGLT2 Inhibitors in Patients with Single Ventricle Congenital Heart Disease and Fontan Circulatory Failure

Anusha Konduri, Caroline West, Ray Lowery, Tiffany Hunter, Audrey Jarosz, Sunkyung Yu, Heang M Lim, Amanda D McCormick, Kurt R Schumacher, David M Peng

Pediatric Cardiology · 2025

DOI: 10.1007/s00246-023-03332-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Cardiology, 2025. Verfasst von Anusha Konduri und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Congenital Heart Center, Ann Arbor, MI, USA. anushkonduri@gmail.com. Hauptthemen laut MEDLINE: Fontan Procedure, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Heart Defects, Congenital. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure is the leading cause of morbidity and mortality in patients with Fontan circulation. Sodium-glucose-cotransporter 2 inhibitors (SGLT2i) have become a mainstay of heart failure therapy in adult patients, however, there remains a paucity of literature to describe its use in pediatric heart failure patients, especially those with single ventricle physiology. We describe our early experience using SGLT2i in patients with single ventricle congenital heart disease surgically palliated to the Fontan circulation. We conducted a single-center retrospective chart review of all patients with Fontan circulation who were initiated on an SGLT2i from January 1, 2022 to March 1, 2023. Patient demographics, diagnoses, clinical status, and other therapies were collected from the electronic medical record. During the study period, 14 patients (median age 14.5 years, range 2.0-26.4 years) with Fontan circulation were started on a SGLT2i. Mean weight was 54 kg (range 11.6-80.4 kg). Median follow-up since SGLT2i initiation was 4.1 months (range 13 days-7.7 months). Four patients had a systemic left ventricle and 10 had a systemic right ventricle. Half the patients had Fontan Circulatory Failure with reduced Ejection Fraction (FCFrEF) of the systemic ventricle and the other half had Fontan Circulatory Failure with preserved Ejection Fraction (FCFpEF) of the systemic ventricle. In addition, 3 patients experienced Protein Losing Enteropathy (PLE) and 2 patients had plastic bronchitis, one of whom also was diagnosed with chylothorax. There were no genitourinary infections, hypoglycemia, ketoacidosis, hypotension or other significant adverse effects noted in our patient population. One patient experienced significant diuresis and transient acute kidney injury. Patients with FCFrEF showed a decrease in natriuretic peptide levels. Given the lack of proven therapies, demonstrated benefits of SGLT2i in other populations, and some suggestion of efficacy in Fontan circulation, further study of SGTLT2i in patients with Fontan circulation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fontan ProcedureSodium-Glucose Transporter 2 InhibitorsHeart FailureHeart Defects, CongenitalUniventricular HeartHeart VentriclesHumansFemaleMaleRetrospective StudiesChildAdolescentChild, PreschoolAdultYoung AdultTreatment Outcome

Stichwörter der Autor:innen

Fontan physiologyHeart failureSingle ventricle circulationSodium-glucose-cotransporter 2 Inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • University of Michigan Congenital Heart Center, Ann Arbor, MI, USA. anushkonduri@gmail.com.
  • University of Michigan Congenital Heart Center, Ann Arbor, MI, USA.

Zitieren

APA

Konduri, A., West, C., Lowery, R., Hunter, T., Jarosz, A., Yu, S., Lim, H. M., McCormick, A. D., Schumacher, K. R., & Peng, D. M. (2025). Experience with SGLT2 Inhibitors in Patients with Single Ventricle Congenital Heart Disease and Fontan Circulatory Failure. Pediatric Cardiology. https://doi.org/10.1007/s00246-023-03332-5

Vancouver

Konduri A, West C, Lowery R, Hunter T, Jarosz A, Yu S, et al. Experience with SGLT2 Inhibitors in Patients with Single Ventricle Congenital Heart Disease and Fontan Circulatory Failure. Pediatric Cardiology. 2025. doi:10.1007/s00246-023-03332-5

BibTeX
@article{Konduri2025,
  author = {Konduri, Anusha and West, Caroline and Lowery, Ray and Hunter, Tiffany and Jarosz, Audrey and Yu, Sunkyung and Lim, Heang M and McCormick, Amanda D and Schumacher, Kurt R and Peng, David M},
  title = {Experience with SGLT2 Inhibitors in Patients with Single Ventricle Congenital Heart Disease and Fontan Circulatory Failure},
  journal = {Pediatric Cardiology},
  year = {2025},
  doi = {10.1007/s00246-023-03332-5}
}
Kostenlos starten →